Teva introduces generic version of Grifulvin
NORTH WALES, Pa. Teva Pharmaceuticals is pleased to announce the introduction and availability of griseofulvin oral suspension USP (microsize). This product is AB rated and bioequivalent to Grifulvin V suspension. Griseofulvin Oral Suspension is available in a 125 mg/5 mL strength, in a 120 mL bottle size.
“Our customers count on Teva for a continuous supply of new generic products,” stated John Denman, vice president of Sales and Marketing. “With the launch of griseofulvin oral suspension, we add another quality product to our broad line of affordable generic pharmaceuticals.”
Grifulvin, an OrthoNeutrogena product, is indicated for such pediatric fungal infections as ringworm or athlete’s foot. Annual sales of griseofulvin oral suspension USP in the United States were approximately $38 million for the twelve months ended March 2007, according to IMS Health data.
FDA approves two new APP generic medications
SCHAUMBURG, Ill. The Food and Drug Administration approved APP Pharmaceuticals’ new drug applications for caffeine citrate oral solution at 20 milligrams/milliliter and for bleomycin sulfate for injection.
Caffeine citrate oral solution, the generic version of Bedford Labs’ Cafcin, is a treatment used for premature infants who have apnea, a condition where babies stop breathing during sleep for a brief amount of time, according to published reports.
Bleomycin is a treatment for cancer, a generic of Bristol-Myer’s Blenoxane, although it works in combination with other medicines. As a result of the recent FDA approval, APP Pharma stock increased to $10.33, a three-cent increase per share.
Shares of Labopharm rise with positive Trazodone study
NEW YORK Positive results on Trazodone, a once-daily anti-depressant pill, caused shares of Labopharm to rise on Friday.
According to published reports, Trazodone is a pill whose main goal is to improve a patient’s quality of sleep. The study reveals that this goal was met, with 412 patients showing that a once-daily version is effective and also inhibits a patient from awaking as frequently during the night.
The stock for Labopharm rose by 18.7 percent, about 37 cents, increasing the stock price to $2.35 in morning trading. Over the past year, the stock has ranged between 63 cents and $7.21.
The Food And Drug Administration already approved the twice-daily version of Trazodone, and Labopharm is planning to file a new drug application for its newest version of Trazodone with the FDA later in the year.